Mooney H, Austad KE, Campbell EG, Avorn J, Lu Z, Kesselheim AS - JAMA Health Forum
- Research Publications
- Regulation and Clinical Evidence
Summary:
Physicians surveyed in 2011 and 2024 increasingly recognized the value of the materials they receive from drug companies, but remained concerned about the impact on public trust in medicine. To address these concerns, professional societies, payers, and regulators should collaborate to create unbiased educational resources for clinicians on the efficacy and safety of drugs.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
The Impact of Semantics in Medicines Regulation
Costa E, Kesselheim AS - Journal of Law, Medicine, & Ethics
- Commentary & Opinion
- Innovation Incentives and Competition
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.